

David L. Pompliano, PhD takes on the role of CEO at BioLeap

February 24, 2009

“David has been working very closely with me and the BioLeap team as an Adviser to the company, and is uniquely qualified to take on this important leadership role.”, commented John Kulp, PhD, Chairman and Chief Technical Officer of BioLeap. “His executive experience managing drug discovery teams will enable him to drive BioLeap to realize its corporate mission of developing numerous high-quality clinical candidates for anti-infectives and other, often intractable, therapeutic targets. David brings a deep knowledge of the requirements for commercially-successful drugs, which will provide the basis for strategically prioritizing BioLeap's programs and relationships. I believe he is fully up to the challenge of exploiting BioLeap's next generation, structure-based technology platform to significantly increase the success rate and capital efficiency of bringing novel compounds to clinical trials. His broad network of relationships across the industry will serve BioLeap well in establishing business engagements and collaborations. We look forward to David fostering BioLeap's growth to the next level.”

“BioLeap has created a sophisticated lead discovery and optimization platform based on fundamental thermodynamic principles which vastly improves the efficiency of drug discovery”, said Pompliano. “BioLeap offers new approaches to difficult targets that have not yielded to traditional wet lab screening, to “hot” targets that have hit a wall in lead optimization, and to quickly designing non-obvious chemical structures as fast-followers to competitor’s compounds.”

Dr. Pompliano has eighteen years of leadership experience in the pharmaceutical industry with a focus on driving strategic change in research and development. Most recently he served as Vice President, Worldwide Basic Head, Vaccines and Infectious Diseases Franchise for Merck Research Laboratories. Prior to Merck, David was Vice President, Head of Biology, Microbial Musculoskeletal and Proliferative Diseases Center for Excellence in Drug Discovery at GlaxoSmithKline. Earlier in his career, David served as Executive Director and Head of Antimicrobial and Angiogenesis Research at DuPont Pharmaceuticals and as Director in the Department of Biochemistry at Merck Research Laboratories. As a drug hunter, David has contributed to the discovery or development of three marketed drugs (Tykerb, Promacta and Altabax) and three additional drugs that have reached clinical proof of concept. He is an internationally recognized scientist and innovator who has published >50 research papers, has given >30 invited lectures internationally and holds three patents for novel methods in drug discovery.

Dr. Pompliano received his B.S. (Chemistry) at the University of Virginia and his Ph.D. (Chemistry) from Stanford University. David was a NIH Post-Doctoral Fellow at Harvard University in the Department of Chemistry.

About BioLeap:

BioLeap is an emerging drug discovery company enabled by the next generation of computational fragment-based design technology. BioLeap’s design platform quickly predicts binding affinity based on thermodynamic principles giving drug designers new insights to efficiently create non-obvious molecules and improve existing molecules. Lack of chemical diversity has blocked the progress of many high-priority targets during the lead identification and lead optimization phase for failure to provide either a suitable chemical starting point or a replacement structural class to a doomed lead series. BioLeap’s technology provides a viable alternative to high-throughput screening and traditional shape-based “docking” approaches. BioLeap has identified lead compounds in four collaborative ventures and is seeking new partners who are interested in exploiting its compelling compound design and engineering platform.

Contact:

Gerry Evans, EVP
BioLeap
215-371-2874
ghe@bioleap.com